Blinatumomab
| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Mouse |
| Target | CD19, CD3 |
| Clinical data | |
| Trade names | Blincyto |
| Other names | AMG103, MT103, Blina |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614061 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Metabolism | degradation into small peptides and amino acids |
| Elimination half-life | 2.11 hours |
| Excretion | urine (negligible) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2367H3577N649O772S19 |
| Molar mass | 54086.56 g·mol−1 |
| (what is this?) (verify) | |
Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used for the treatment of Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that specifically targets the CD19 antigen present on B cells. Blinatumomab is given via intravenous infusion.
Blinatumomab was approved for medical use in the United States in December 2014, in Australia in November 2015, in Canada in March 2016, and in the European Union in November 2023.